Novel immunostimulatory antibodies: What's next?

Privacy - Preserving Data Mining at 10: Whats Next?

It has been 10 years since the first papers entitled “Privacy–Preserving Data Mining” appeared. The past decade has witnessed a flood of papers with new techniques to protect and mine data, but little real– world impact. Is privacy dead? Or are there still challenges that must be addressed? This talk will begin with a brief retrospective on advances in privacy–preserving data mining. We will th...

Virotherapy, gene transfer and immunostimulatory monoclonal antibodies

Malignant cells are susceptible to viral infection and consequent cell death. Virus-induced cell death is endowed with features that are known to stimulate innate and adaptive immune responses. Thus danger signals emitted by cells succumbing to viral infection as well as viral nucleic acids are detected by specific receptors, and tumor cell antigens can be routed to professional antigen-present...

Therapeutic potential of immunostimulatory monoclonal antibodies.

The aim of cancer immunotherapy is to employ the specificity of the immune system to provide a more effective, less toxic, treatment compared with conventional therapies. Although many strategies have been used to try to generate effective anticancer immune responses, very few have reached mainstream clinical use. A new approach introduced over the last few years is to use immunostimulatory mAb...

Virotherapy, gene transfer and immunostimulatory monoclonal antibodies

Immunostimulatory combinations: designing the next generation of vaccine adjuvants.

Agents that activate dendritic cells are essential components for vaccines and can be conceptualized as molecular adjuvants. Other molecular adjuvants affect downstream factors that shape the resulting immune response. This review provides a compendium of recently studied molecular adjuvants, focusing on CD8+ T cell responses, which have important roles in HIV vaccines. Reference is also made t...